Paper36926237
Current status and prospect of treatments for recurrent hepatocellular carcinoma.
Yang YQ and 7 others. World J Hepatol, 2023. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Current status and prospect of treatments for recurrent hepatocellular carcinoma. Papers, record 36926237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36926237
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References185
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35372050 | Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review. | Front Oncol | 2022 | https://conductscience.org/library/papers/35372050 | PubMed |
| 2 | 35287627 | Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35287627 | PubMed |
| 3 | 31500650 | From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31500650 | PubMed |
| 4 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 5 | 27598831 | Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials. | Scand J Gastroenterol | 2016 | https://conductscience.org/library/papers/27598831 | PubMed |
| 6 | 26981887 | Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. | Oncotarget | 2016 | https://conductscience.org/library/papers/26981887 | PubMed |
| 7 | 32108433 | Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. | Cancer Med | 2020 | https://conductscience.org/library/papers/32108433 | PubMed |
| 8 | 28728985 | Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment. | Int J Surg | 2017 | https://conductscience.org/library/papers/28728985 | PubMed |
| 9 | 35693455 | Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. | Hepatoma Res | 2022 | https://conductscience.org/library/papers/35693455 | PubMed |
| 10 | 23393371 | Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma. | Anticancer Res | 2013 | https://conductscience.org/library/papers/23393371 | PubMed |
| 11 | 22507499 | Re-resection for metachronous primary hepatocellular carcinoma: is it justified? | ANZ J Surg | 2012 | https://conductscience.org/library/papers/22507499 | PubMed |
| 12 | 32940044 | Long-term clinical benefit of Peg-IFNα and NAs sequential anti-viral therapy on HBV related HCC. | Neoplasma | 2021 | https://conductscience.org/library/papers/32940044 | PubMed |
| 13 | 19095782 | Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. | Radiology | 2009 | https://conductscience.org/library/papers/19095782 | PubMed |
| 14 | 31058698 | Surgery for Recurrent Hepatocellular Carcinoma: Achieving Long-term Survival. | Ann Surg | 2021 | https://conductscience.org/library/papers/31058698 | PubMed |
| 15 | 31774468 | Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/31774468 | PubMed |
| 16 | 35360522 | R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. | JHEP Rep | 2022 | https://conductscience.org/library/papers/35360522 | PubMed |
| 17 | 23980077 | Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23980077 | PubMed |
| 18 | 22157201 | Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. | Radiology | 2012 | https://conductscience.org/library/papers/22157201 | PubMed |
| 19 | 31730015 | Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. | Cancer Imaging | 2019 | https://conductscience.org/library/papers/31730015 | PubMed |
| 20 | 17006925 | Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. | Hepatology | 2006 | https://conductscience.org/library/papers/17006925 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42756218 | Sodium alginate-based dual-responsive nanoparticles co-loaded with baicalin and doxorubicin induce ferroptosis in hepatocellular carcinoma associated with the PI3K/AKT/FoxO3α axis regulation. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42756218 | PubMed |
| 42169912 | Advances in mitophagy research in hepatocellular carcinoma: mechanisms and therapeutic implications. | J Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42169912 | PubMed |
| 41937376 | Prognostic Value and Related Molecular Mechanisms of miR-5003-3p in Hepatocellular Carcinoma. | Can J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41937376 | PubMed |
| 41723802 | Construction of a prognostic model based on protein post-translational modification genes for prediction of immune characteristics and therapeutic response in hepatocellular carcinoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41723802 | PubMed |
| 40956482 | Construction of a prognostic model for hepatocellular carcinoma based on necrosis by sodium overload-related genes and identification of ANKRD13B as a new prognostic marker. | Funct Integr Genomics | 2025 | https://conductscience.org/library/papers/40956482 | PubMed |
| 40870868 | Recent Advances in Magnetic Resonance Imaging for the Diagnosis of Liver Cancer: A Comprehensive Review. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40870868 | PubMed |
| 40790550 | Elucidating the role of AC026412.3 in hepatocellular carcinoma: a prognostic disulfidptosis-related LncRNAs model perspective. | BMC Gastroenterol | 2025 | https://conductscience.org/library/papers/40790550 | PubMed |
| 40244531 | Based on disulfidptosis, unveiling the prognostic and immunological signatures of Asian hepatocellular carcinoma and identifying the potential therapeutic target ZNF337-AS1. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40244531 | PubMed |
| 40066093 | Efficacy and prognostic impact of preoperative risk factors for salvage liver transplantation and repeat hepatectomy in patients with early-stage recurrent hepatocellular carcinoma: a propensity score-matched analysis. | Front Oncol | 2025 | https://conductscience.org/library/papers/40066093 | PubMed |
| 40057688 | Radiofrequency ablation versus stereotactic body radiotherapy for recurrent hepatocellular carcinoma: a multicenter, propensity score matching analysis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40057688 | PubMed |
| 39713637 | Systematic Analysis of Disulfidptosis-Related lncRNAs in Hepatocellular Carcinoma with Vascular Invasion Revealed That AC131009.1 Can Promote HCC Invasion and Metastasis through Epithelial-Mesenchymal Transition. | ACS Omega | 2024 | https://conductscience.org/library/papers/39713637 | PubMed |
| 39498055 | Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights. | Heliyon | 2024 | https://conductscience.org/library/papers/39498055 | PubMed |
| 39453585 | Comparison of Prognostic Outcomes Between Repeat Liver Resection and Particle Therapy for Patients with Recurrent Hepatocellular Carcinoma. | Ann Surg Oncol | 2025 | https://conductscience.org/library/papers/39453585 | PubMed |
| 39354529 | Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39354529 | PubMed |
| 39210306 | Construction of a prognostic model for disulfidptosis-related long noncoding RNAs in R0 resected hepatocellular carcinoma and analysis of their impact on malignant behavior. | BMC Cancer | 2024 | https://conductscience.org/library/papers/39210306 | PubMed |
| 38893206 | Preoperative Bone Loss Predicts Decreased Survival Associated with Microvascular Invasion after Resection of Hepatocellular Carcinoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38893206 | PubMed |
| 38494848 | The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma. | J Cell Mol Med | 2024 | https://conductscience.org/library/papers/38494848 | PubMed |
| 37941812 | Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2023 | https://conductscience.org/library/papers/37941812 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36926237
GET https://conductscience.org/api/papers/v1/36926237/references?page=2